Patience, we're really, really close - just keep doing the math if you get anxious. Firmly believe $30M from CPI-300 ($23.5M sales milestone + $7M in royalties) by the end of '13 is set in stone. Edgemont only needs to generate $60M in sales from an existing market base for max dose Bupropion that is $200M per year - selling the only single dose product available (math is 12% royalty on $60M = $7.2M which triggers the $23.5M milestone). Everything else - migraine, PAR, ED partner, etc. - is all on top. $30M is more than the whole market cap of IGXT at today's price.
For those who feel I'm not looking for anything on the down side - I still don't like how communications are worded. Example, in the recent earnings release Zerbe said "We expect CPI-300 to be commercialized this summer". Expect, not expect - we WILL commercialize CPI-300 this summer. I know it might be considered semantics, but saying 'expect' does not show absolute confidence. I have no doubt the product will launch on time, my 'down side' is just how / when things are stated.
Hopefully they are making up for it by starting to buy back stock - even small amounts to keep from getting bought out on the cheap.
Market Data 
Markets 
AI
